S&P 500   3,226.74 (+0.91%)
DOW   26,847.91 (+0.77%)
QQQ   261.00 (+0.24%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,226.74 (+0.91%)
DOW   26,847.91 (+0.77%)
QQQ   261.00 (+0.24%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,226.74 (+0.91%)
DOW   26,847.91 (+0.77%)
QQQ   261.00 (+0.24%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,226.74 (+0.91%)
DOW   26,847.91 (+0.77%)
QQQ   261.00 (+0.24%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
Log in

NYSE:ABBVAbbVie Stock Price, Forecast & News

$99.80
+0.93 (+0.94 %)
(As of 07/15/2020 02:20 PM ET)
Add
Compare
Today's Range
$98.82
Now: $99.80
$100.12
50-Day Range
$89.98
MA: $95.30
$99.35
52-Week Range
$62.55
Now: $99.80
$100.69
Volume3.08 million shs
Average Volume11.11 million shs
Market Capitalization$147.38 billion
P/E Ratio17.66
Dividend Yield4.82%
Beta0.86
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More
AbbVie logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 5.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.65 per share
Book Value($5.53) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Employees30,000
Outstanding Shares1,476,742,000
Market Cap$147.38 billion
Next Earnings Date7/31/2020 (Confirmed)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock been impacted by COVID-19 (Coronavirus)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABBV stock has increased by 17.5% and is now trading at $99.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AbbVie?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for AbbVie.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) issued its earnings results on Friday, May, 1st. The company reported $2.42 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.25 by $0.17. The firm had revenue of $8.62 billion for the quarter, compared to analysts' expectations of $8.31 billion. AbbVie had a negative return on equity of 169.80% and a net margin of 24.77%. The business's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.14 EPS. View AbbVie's earnings history.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Wednesday, June 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 annualized dividend and a dividend yield of 4.73%. The ex-dividend date of this dividend is Tuesday, July 14th. View AbbVie's dividend history.

How will AbbVie's stock buyback program work?

AbbVie declared that its board has initiated a stock buyback plan on Thursday, December 13th 2018, which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 3.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50-50 billion.

What price target have analysts set for ABBV?

17 brokers have issued 1 year price targets for AbbVie's shares. Their forecasts range from $90.00 to $125.00. On average, they anticipate AbbVie's stock price to reach $106.80 in the next twelve months. This suggests a possible upside of 7.1% from the stock's current price. View analysts' price targets for AbbVie.

Has AbbVie been receiving favorable news coverage?

News headlines about ABBV stock have been trending negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AbbVie earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news about AbbVie.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.15%), DNB Asset Management AS (0.07%), Hamlin Capital Management LLC (0.05%), Gateway Investment Advisers LLC (0.04%), Manning & Napier Group LLC (0.03%) and TIAA FSB (0.03%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Hamlin Capital Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, Gateway Investment Advisers LLC, 6 Meridian, Factory Mutual Insurance Co., Municipal Employees Retirement System of Michigan, IFM Investors Pty Ltd, and HNP Capital LLC. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Envestnet Asset Management Inc., State of Alaska Department of Revenue, Contravisory Investment Management Inc., Wesbanco Bank Inc., Veracity Capital LLC, Mountain Capital Investment Advisors Inc, and Canandaigua National Corp. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $99.73.

How big of a company is AbbVie?

AbbVie has a market capitalization of $147.28 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.